Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 2/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 6/20 | 0.45 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | INSR | P06213 | 6/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22507833 | 0.90 | EGFR (0.43) | ZAP70LRRK2EGFR | |
| SCHEMBL26324772 | 0.87 | EGFR (0.40) | ZAP70LRRK2EGFR | |
| SCHEMBL26324590 | 0.86 | LRRK2 (0.39) | ZAP70LRRK2EGFR | |
| SCHEMBL23761671 | 0.86 | EGFR (0.54) | LRRK2ALKEGFR | |
| SCHEMBL31630575 | 0.86 | EGFR (0.54) | LRRK2ALKEGFR | |
| SCHEMBL26324473 | 0.83 | LRRK2 (0.39) | LRRK2EGFR | |
| SCHEMBL26324859 | 0.82 | LRRK2 (0.37) | ZAP70LRRK2EGFR | |
| SCHEMBL29594720 | 0.81 | ALK (0.49) | ZAP70LRRK2MAPK3ALKINSR | |
| SCHEMBL28728761 | 0.79 | ALK (0.60) | MAPK3ALKEGFRINSRIGF1R | |
| SCHEMBL28728854 | 0.79 | LRRK2 (0.47) | ZAP70LRRK2MAPK3ALKINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230293535-A1 | ERBB/BTK INHIBITORS | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293535-A1 | ERBB/BTK INHIBITORS | ERBB2, BTK, ERBB3 | ZAP70 50/4885LRRK2 225/4885MAPK3 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.